Literature DB >> 12199987

[Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection].

Nuria Vallejo Camazón1, Dolors Rodríguez Pardo, Antonio Sánchez Hidalgo, María Pilar Tornos Mas, Esteban Ribera, Jordi Soler Soler.   

Abstract

Prolongation of the QT interval is associated with a high risk of serious ventricular tachyarrhythmias, usually torsade de pointes (TdP) polymorphic ventricular tachycardia, although monomorphic ventricular tachycardia may also develop. Both congenital and acquired forms have been reported, acquired forms being much more prevalent. An association between human immunodeficiency virus (HIV) infection and a higher rate of dilated cardiomyopathy has also been recognized. The severity of immunodeficiency seems to influence both the incidence and severity of cardiomyopathy. A higher prevalence of QT prolongation has been reported among hospitalized HIV-positive patients with HIV infection, possibly related to drugs prescribed for such patients or to an acquired form of long QT syndrome arising from HIV infection. We report a case of QT prolongation and development of ventricular arrhythmia in one HIV patient that started with intravenous clarithromycin and cotrimoxazole therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12199987     DOI: 10.1016/s0300-8932(02)76720-1

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  6 in total

1.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

2.  QTc interval prolongation in patients with HIV and AIDS.

Authors:  Mahmoud U Sani; Basil N Okeahialam
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 3.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 4.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.

Authors:  W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-08

6.  QTc interval prolongation in HIV-infected patients: a case-control study by 24-hour Holter ECG recording.

Authors:  Alessandra Fiorentini; Nicola Petrosillo; Angelo Di Stefano; Stefania Cicalini; Laura Borgognoni; Evangelo Boumis; Luigi Tubani; Pierangelo Chinello
Journal:  BMC Cardiovasc Disord       Date:  2012-12-23       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.